Chimeric antigen receptors against axl or ror2 and methods of use thereof
AssigneesExuma Biotech Corp., BioAtla, Inc.
InventorsGregory Ian FROST, James Joseph ONUFFER, Jr., Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.
Claims23
An isolated nucleic acid encoding a chimeric antigen receptor (CAR) for binding Axl, said CAR comprising:
- a) a conditionally active antigen-specific targeting region (ASTR) that exhibits an increased binding to Axl at a pH of 6.7 compared to a pH of 7.4;
- b) a transmembrane domain;
- and
- c) an intracellular activating domain, wherein the transmembrane domain is located between the ASTR and the intracellular activating domain.
A chimeric antigen receptor (CAR) for binding Axl, comprising:
- a) a conditionally active antigen-specific targeting region (ASTR) that exhibits an increased binding to Axl at a pH of 6.7 compared to a pH of 7.4;
- b) a transmembrane domain;
- and
- c) an intracellular activating domain, wherein the transmembrane domain is located between the ASTR and the intracellular activating domain.
A chimeric antigen receptor (CAR) for binding Ror2, comprising:
- a) a conditionally active antigen-specific targeting region (ASTR) that exhibits an increased binding to Ror2 at a pH of 6.7 compared to a pH of 7.4;
- b) a transmembrane domain;
- and
- c) an intracellular activating domain, wherein the transmembrane domain is located between the ASTR and the intracellular activating domain.
Dependencies are inferred from the claim text.